

# Biosynthesis of ionotropic acetylcholine receptors requires the evolutionarily conserved ER membrane complex

Magali Richard<sup>a,b,c</sup>, Thomas Boulin<sup>a,b,c</sup>, Valérie J. P. Robert<sup>a,b,c,1</sup>, Janet E. Richmond<sup>d</sup>, and Jean-Louis Bessereau<sup>a,b,c,2</sup>

<sup>a</sup>Institute of Biology of Ecole Normale Supérieure, 75005 Paris, France; <sup>b</sup>Institut National de la Santé et de la Recherche Médicale U1024, 75005 Paris, France; <sup>c</sup>Centre National de la Recherche Scientifique, Unité Mixte de Recherche 8197, 75005 Paris, France; and <sup>d</sup>Department of Biological Sciences, University of Illinois, Chicago, IL 60607

Edited by Linda M. Hendershot, St. Jude Children's Research Hospital, Memphis, TN, and accepted by the Editorial Board January 24, 2013 (received for review September 19, 2012)

The number of nicotinic acetylcholine receptors (AChRs) present in the plasma membrane of muscle and neuronal cells is limited by the assembly of individual subunits into mature pentameric receptors. This process is usually inefficient, and a large number of the synthesized subunits are degraded by endoplasmic reticulum (ER)-associated degradation. To identify cellular factors required for the synthesis of AChRs, we performed a genetic screen in the nematode *Caenorhabditis elegans* for mutants with decreased sensitivity to the cholinergic agonist levamisole. We isolated a partial loss-of-function allele of *ER membrane protein complex-6 (emc-6)*, a previously uncharacterized gene in *C. elegans*. *emc-6* encodes an evolutionarily conserved 111-aa protein with two predicted transmembrane domains. EMC-6 is ubiquitously expressed and localizes to the ER. Partial inhibition of EMC-6 caused decreased expression of heteromeric levamisole-sensitive AChRs by destabilizing unassembled subunits in the ER. Inhibition of *emc-6* also reduced the expression of homomeric nicotinic-sensitive AChRs and GABA<sub>A</sub> receptors in *C. elegans* muscle cells. *emc-6* is orthologous to the yeast and human *EMC6* genes that code for a component of the recently identified ER membrane complex (EMC). Our data suggest this complex is required for protein folding and is connected to ER-associated degradation. We demonstrated that inactivation of additional EMC members in *C. elegans* also impaired AChR synthesis and induced the unfolded protein response. These results suggest that the EMC is a component of the ER folding machinery. AChRs might provide a valuable proxy to decipher the function of the EMC further.

Genes coding for nicotinic acetylcholine receptor (AChR) subunits form an evolutionarily conserved family, which includes a large repertoire of ionotropic receptors gated by acetylcholine (ACh). In mammals, there are at least 16 different genes encoding AChR subunits. Each subunit is made up of a large extracellular domain, four transmembrane segments (M1–M4), and a variably long intracellular loop between M3 and M4. Individual subunits assemble into homo- or heteropentameric receptors with distinct pharmacological and biophysical properties (reviewed in ref. 1). Interestingly, the assembly of AChRs seems rather slow and inefficient, which is a feature common to several multimeric transmembrane complexes, such as GABA<sub>A</sub> receptors (2) or cystic fibrosis transmembrane conductance regulator (CFTR) receptors (3). In vertebrate muscle cells, only 30% of the synthesized  $\alpha$  subunits finally assemble into a mature pentamer (4). In neurons, a significant number of AChRs are also found in intracellular compartments (5). Although the physiological significance of AChR intracellular retention is not completely understood, it potentially has diverse pathological implications. For example, a rare mutation in the human  $\beta 4$  AChR subunit has been linked to amyotrophic lateral sclerosis (6), and this mutation was shown to impair the export of  $\alpha 4\beta 4$  AChRs from the endoplasmic reticulum (ER) (7). ER retention of AChRs was also proposed to influence ER stress and the unfolded protein response (UPR) in dopaminergic neurons (8). In the smoker's brain, an enhancement

of AChR expression likely contributes to tobacco addiction. This up-regulation involves a chaperone activity of nicotine, which enhances the assembly of specific receptor species and their export from the ER, together with a reduced degradation of AChR subunits by the proteasome system (9–11).

The overall efficiency of AChR biosynthesis is dependent on multiple processes in the ER and in early secretory compartments (reviewed in ref. 12). AChR subunits enter the ER cotranslationally in an unfolded state via the Sec61 translocon. Transient interactions with ER resident components of the biosynthetic machinery, such as BiP (13, 14), calnexin (15, 16), and ERp57 (17), then influence the folding process and protect immature subunits from degradation. Folding subunits are exposed to a variety of enzymes that catalyze posttranslational modifications (including glycosylation and palmitoylation) and regulate protein expression (18–20). Assembly of the subunits is sequential, and intermediates of certain receptors, such as muscle AChRs, have sufficient  $t_{1/2}$ s to be isolated and characterized (reviewed in ref. 21). ER retention or retrieval signals prevent the exit of unassembled or partially assembled AChR subunits. For example, an ER retention signal present in the M1 transmembrane segment of the subunits is masked by receptor assembly to allow ER exit (22). Unassembled subunits are eventually degraded through the ER-associated degradation (ERAD) machinery (23). ER export signals have also been demonstrated to enhance the recruitment of receptors into ER exit sites (24). In addition, degradation signals present in the cytoplasmic M3–M4 subunit loop (25, 26) must be masked for ER exit licensing. The cytoplasmic M3–M4 loop is also involved in interactions with adaptor proteins, such as the small cytoplasmic chaperone 14-3-3 (27) or the UBXD4 protein (28).

Despite its physiological and pathological importance, relatively few cellular factors are known to control AChR biosynthesis at early steps. This might be due to the difficulty in identifying labile interactions with partially assembled receptors or because receptors interact with large cellular complexes. Genetic screens in model organisms provide a means to identify relevant components in biological networks involved in this specific process. Specifically, the nematode *Caenorhabditis elegans* is a powerful model organism with which to dissect AChR biosynthesis genetically. ACh is the

Author contributions: M.R. and J.-L.B. designed research; M.R., T.B., and J.E.R. performed research; M.R. and V.J.P.R. contributed new reagents/analytic tools; M.R. and J.-L.B. analyzed data; and M.R., T.B., and J.-L.B. wrote the paper.

The authors declare no conflict of interest.

This article is a PNAS Direct Submission. L.M.H. is a guest editor invited by the Editorial Board.

<sup>1</sup>Present address: Laboratory of Molecular and Cellular Biology, Ecole Normale Supérieure, 69007 Lyon, France.

<sup>2</sup>To whom correspondence should be addressed. E-mail: jlbese@biologie.ens.fr.

This article contains supporting information online at [www.pnas.org/lookup/suppl/doi:10.1073/pnas.1216154110/-DCSupplemental](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1216154110/-DCSupplemental).

main excitatory neurotransmitter in *C. elegans*, and at least 29 genes encode AChR subunits (29). Two types of ionotropic AChRs, heteromeric levamisole-sensitive AChRs (L-AChRs) and homomeric nicotine-sensitive AChRs (N-AChRs), are present at the neuromuscular junction (NMJ), the best-characterized cholinergic synapse in the worm (30). L-AChRs are heteropentameric receptors that can be activated by the nematode-specific cholinergic agonist levamisole. Levamisole causes hypercontraction of *C. elegans* body-wall muscles (BWMs) and death of WT worms at high concentrations (31, 32). Genetic screens for resistance to levamisole have identified the structural subunits of the receptor, including three  $\alpha$  subunits (LEV-8, UNC-38, and UNC-63) and two non- $\alpha$  subunits (LEV-1 and UNC-29). The second type of receptor, N-AChR, is activated by nicotine and is insensitive to levamisole. It is most likely homomeric, composed of five ACR-16 subunits (33, 34).

Apart from receptor subunits, genetic screens identified three auxiliary proteins (RIC-3, UNC-50, and UNC-74) required for receptor biosynthesis. RIC-3 was identified in a suppressor screen of neuronal degeneration caused by a gain-of-function mutation in the *C. elegans* AChR composed of DEG-3 and DES-2 subunits (35). RIC-3 is a small integral membrane protein located in the ER that is required for the assembly of at least five distinct AChR receptors in *C. elegans*, including L-AChRs and N-AChRs (35–37). RIC-3 is conserved in flies and mammals, and it can either promote or inhibit the expression of AChRs and 5-HT<sub>3</sub> receptors in heterologous systems (reviewed in ref. 12). Recent analysis suggests that RIC-3 activity depends on its expression level; at low levels, RIC-3 behaves as an ER chaperone promoting AChR assembly, whereas high expression levels cause ER retention through long-lived interactions with AChRs (38). UNC-50 was identified in a screen for resistance to levamisole. UNC-50 is the ortholog of GMH1, a transmembrane protein conserved from yeast to humans, which interacts with a guanine nucleotide exchange factor of the small G protein Arf and potentially regulates COPI-dependent trafficking events. UNC-50 localizes to the Golgi apparatus and promotes the targeting of L-AChRs to the plasma membrane by preventing routing and degradation in lysosomes (39). UNC-74 is a predicted thio-redoxin necessary for L-AChR expression, but its role has not been fully characterized. Interestingly, expression of L-AChRs in *Xenopus* oocytes not only requires the five receptor subunits but the three auxiliary proteins RIC-3, UNC-50, and UNC-74 as well (36). Recently, the ER resident transmembrane proteins NRA-2/nicalin (nicastrin-like protein) and NRA-4/nodal modulator (NOMO), were proposed to regulate L-AChR subunit composition and stoichiometry (40).

To identify additional components required for AChR assembly and folding, we designed a genetic screen for mutants with only partially decreased sensitivity to the cholinergic agonist levamisole, because screens for complete resistance to levamisole are likely saturated. Such mutants completely paralyze on high levamisole concentration within a few hours but subsequently adapt within 12–16 h and recover motility in contrast to WT worms (41, 42). Here, we identify and characterize in vivo the ER membrane protein complex-6 (*emc-6*) gene. We demonstrate that EMC-6 is required for the proper assembly of AChRs through the function of an evolutionarily conserved complex involved in ER homeostasis.

## Results

**Disruption of the Evolutionarily Conserved Gene *emc-6* Confers Partial Resistance to the Cholinergic Agonist Levamisole.** To identify new components involved in AChR metabolism, we used *Mos1*-mediated insertional mutagenesis to generate mutants resistant to the cholinergic agonist levamisole (42). A strain carrying the mutant allele *kr150* was isolated based on its ability to adapt to overnight exposure to 0.6 mM levamisole. A *Mos1* insertion was identified in *kr150* by inverse PCR in the ORF F33D4.7 (Fig. 1A).


This gene is conserved from yeast to humans (Fig. 1B and Table S1), and it was tentatively named *emc-6* because of its homology with the yeast gene *EMC6* (43). Based on cDNA sequencing, the *C. elegans emc-6* messenger is transspliced to the splice leader SL1 and encodes a predicted 111-aa protein with two transmembrane domains (Fig. 1C). Topology prediction programs suggest that the N-terminal region of the protein is cytosolic. The decreased sensitivity to levamisole of *kr150* mutants was rescued by providing a 900-bp genomic fragment containing the *emc-6* coding region (Fig. 1A and D), thus demonstrating that mutating *emc-6* causes the partial resistance to levamisole in this mutant.

Nonquantitative RT-PCR analysis demonstrated that *emc-6* transcript remains in *kr150* mutants. Insertion of the *Mos1* transposon causes the replacement of the conserved ultimate amino acid by four unrelated residues followed by a STOP codon, a cryptic polyadenylation site being used in the *Mos1* sequence (Fig. S1A). Quantitative RT-PCR analysis indicated, however, that the level of this *emc-6* mRNA was severely reduced compared with the WT [ $21 \pm 5\%$  at L2 stage and  $8 \pm 1\%$  at L4 stage (mean  $\pm$  SEM);  $n = 4$ ] (Fig. S1B). These data suggested that *emc-6(kr150)* is a strong loss-of-function mutant but may not be a null allele (details are provided in Fig. S2). Our attempts to generate a second allele of *emc-6* by noncomplementation screening after EMS mutagenesis (30,155 F1 animals screened) was unsuccessful, suggesting that *kr150* is a particular hypomorphic allele of *emc-6* and that *emc-6* might be an essential gene.

Apart from resistance to levamisole, the *kr150* mutation is associated with general phenotypic defects, including embryonic lethality, growth retardation, and reduced brood size (Fig. S2). Unfortunately, the rescue of these phenotypes could not be quantitatively scored because the transgene expressing *emc-6* from a genomic fragment was, by itself, causing partial embryonic lethality and significant developmental defects. Because adaptive resistance to levamisole is usually not associated with developmental phenotypes (e.g., *lev-10*, *lev-9*, *oig-4*, *molo-1* mutant), these data suggest that *emc-6* supports general functions apart from its role in cholinergic neurotransmission.

**EMC-6 Is Required in Muscle for L-AChR Expression.** To characterize the *emc-6* expression pattern, we built a transcriptional reporter expressing GFP under the control of *emc-6* regulatory sequences. Surprisingly, we observed that transgenes driving GFP expression under the control of the 263-bp promoter sequence used for *emc-6* rescue experiments induced lethality and did not transmit GFP expression after one generation. Despite significant efforts, we failed to establish stable expression of this transcriptional reporter and could only acquire pictures of mosaic F1 animals (Fig. S3A). In these mosaic animals, GFP was detected in almost all tissues, including neurons and muscle cells. The very unusual toxicity of a small promoter fragment suggested that it might trigger sequence-specific epigenetic mechanisms. To bypass this technical issue, we characterized the expression pattern of the *Caenorhabditis briggsae* ortholog of *emc-6* (*Cb-emc-6*) in *C. elegans*. *Cb-EMC-6* and *C. elegans Ce-EMC-6* protein sequences are 98% identical. Expression of the genomic locus of *Cb-emc-6* in *emc-6(kr150)* was sufficient to rescue the levamisole resistance of *emc-6(kr150)* mutants (Fig. S3B). Interestingly, transgenic expression of *Cb-emc-6* was nontoxic in *C. elegans*. We therefore expressed a nuclear GFP under the control of the *C. briggsae*-promoting sequence of *emc-6* in *C. elegans* (Fig. S3C). We were able to detect GFP expression in every tissue from the threefold stage to adulthood. Altogether, these results suggest that *emc-6* is ubiquitously expressed.

To test in which tissue EMC-6 was required for L-AChR expression, we used the muscle-specific *Pmyo-3* promoter or the neuron-specific *Prab-3* promoter to express the *emc-6* cDNA in *emc-6(kr150)* mutants (Fig. 2A). Unlike the *Prab-3::emc-6* construct, *Pmyo-3::emc-6* fully rescued levamisole resistance of *emc-6*



**Fig. 1.** *emc-6* encodes a conserved transmembrane protein. (A) Structure of the *emc-6* genomic locus. *emc-6* is predicted to be the upstream gene of an operon ([www.wormbase.org](http://www.wormbase.org)). Black boxes represent the coding regions, and gray boxes represent the 5' untranslated region. The black triangle illustrates the site of *Mos1* insertion in *kr150*. SL1, SL1 transspliced leader; SL2, SL2 transspliced leader. (B) ClustalX alignment of *C. elegans* EMC-6 with orthologs from nematodes, fly, and vertebrates. Predicted transmembrane regions (TM1 and TM2) are boxed. Residues conserved in all species are highlighted in dark gray, residues with strongly similar properties (scoring >0.5) are highlighted in medium gray, and residues with weakly similar properties (scoring ≤0.5) are highlighted in light gray. The position of the *kr150* mutation is indicated by a triangle. (C) EMC-6 topology model based on TMHMM and Topo2 predictions. Residues conserved in all species are labeled in gray. Cter, C-terminus; CYT, cytoplasm; LUM, lumen; Nter, N-terminus. (D) Expression of an *emc-6* genomic fragment rescues levamisole resistance in *kr150* mutants. Gray bars illustrate the percentage of dead animals after overnight exposure to 0.6 mM levamisole, and black bars illustrate the percentage of surviving animals. Three independent transgenic lines were tested. n, number of animals tested. \*\*\**P* < 0.001, Fisher exact probability test.

(*kr150*) mutants. This indicates that *emc-6* functions in BWMs to promote L-AChR surface expression.


**EMC-6 Localizes to the ER.** To assay the subcellular localization of the EMC-6 protein, we expressed an N-terminally tagged EMC-6 construct in the BWMs. As mentioned above, transgenes driving *Ce-emc-6* expression were extremely toxic, and we could only generate a single transgenic line, prompting us to express a tagged version of *C. briggsae* EMC-6 also. BWM expression of either HA::Ce-EMC-6 or GFP::Cb-EMC-6 rescued the *emc-6(kr150)* levamisole resistance phenotype (Fig. 2A). With both constructs, tagged EMC-6 localized to a perinuclear intracellular network reminiscent of ER. Consistently, GFP::Cb-EMC-6 colocalized with tagRFP fused to the ER retention signal KDEL (44) (Fig. 2B). Conversely, the Golgi marker  $\alpha$ -MannosidaseII-tagRFP (45) did not colocalize with HA::Ce-EMC-6 (Fig. 2C). These results demonstrate that both *C. briggsae* and *C. elegans* EMC-6 primarily localize to the ER.

***emc-6* Is Required for Surface Expression of Ligand-Gated Ion Channels at NMJs.** The resistance of *emc-6(kr150)* mutants to levamisole suggested that disrupting *emc-6* impairs L-AChR function. To analyze this defect, we first recorded the electrophysiological response of BWM cells to pressure-applied levamisole and observed a 73% decrease in the response of *emc-6(kr150)* mutants compared with the WT (Fig. 3A). To evaluate the number of L-AChRs present at the synapse, we quantified the L-AChR-

dependent evoked response after stimulation of cholinergic motor neurons and found a 66% reduction in *emc-6(kr150)*. These data suggest that the amount of functional L-AChRs is severely reduced in *emc-6(kr150)* but that the remaining receptors are still clustered at NMJs (Fig. 3B).

To test if these electrophysiological phenotypes might reflect a synaptogenesis defect, we stained cholinergic boutons by immunofluorescence. The staining pattern of the vesicular acetylcholine transporter UNC-17 was indistinguishable between *emc-6(kr150)* and WT animals. By contrast, the staining of L-AChRs was dramatically decreased in *emc-6(kr150)* mutants (Fig. 3C). To quantify the synaptic decrease of the L-AChRs in *emc-6(kr150)*, we generated a knock-in strain carrying the *unc-29* L-AChR subunit endogenously tagged with tagRFP using the *MosTIC* technique (46). Consistent with immunostaining of L-AChRs, we observed an 82% decrease of the amount of L-AChR at the NMJ (Fig. 3D and E). The remaining L-AChRs still formed synaptic clusters in *emc-6(kr150)* mutants. Altogether, these electrophysiological and histological results indicate that *emc-6* is required for the surface expression of L-AChRs.

In WT animals, BWMs sense excitatory cholinergic inputs through heteromeric L-AChRs and homomeric ACR-16-containing N-AChRs, as well as through inhibitory GABAergic input through the UNC-49 GABA<sub>A</sub> receptors. To decipher the specificity of the *emc-6(kr150)* phenotype at NMJs, we recorded the electrophysiological responses of BWM to pressure-ejected nicotine, which stimulates only ACR-16-containing



**Fig. 2.** *emc-6* is required in muscle cells for L-AChR function and localizes to the ER. (A) Expression of an *emc-6* cDNA and GFP::Cb-EMC-6 or HA::Ce-EMC-6 translational fusion in muscle (*Pmyo-3* promoter) but not in neurons (*Prab-3* promoter) rescues levamisole resistance of *emc-6(kr150)* mutants. n, number of tested animals. n.s. (nonsignificant),  $P > 0.05$ ; \*\*\* $P < 0.001$ , Fisher exact probability test. (B) GFP::Cb-EMC-6 fusion proteins localize to the ER. (i) GFP::Cb-EMC-6 and tagRFP::KDEL translational fusions used for expression in BWM (*Pmyo-3* promoter). (ii) Live images of GFP::Cb-EMC-6 and tagRFP::KDEL displaying a reticular staining pattern throughout the cytoplasm surrounding the nucleus. (Scale bars, 5  $\mu$ m.) (iii) Magnified view of the reticulum network. (Scale bars, 2.5  $\mu$ m.) (C) HA::Ce-EMC-6 fusion does not colocalize with a Golgi-resident tagRFP-tagged Mannosidase II protein (MANS::tagRFP). (i) HA::Ce-EMC-6 and MANS::tagRFP used for expression in BWMs (*Pmyo-3* promoter). (ii) Immunostaining with anti-HA and anti-tagRFP antibodies. DAPI staining of cell nuclei. (Scale bars, 5  $\mu$ m.)

N-AChRs, (Fig. 3F) or to GABA (Fig. 3G). We found a 36% decreased response to nicotine and a 57% decreased response to GABA in *emc-6(kr150)* mutants compared with WT animals. These results demonstrate that *emc-6* is required for the surface expression of at least three different types of multimeric ion channels.

***emc-6* Stabilizes L-AChR Subunits Before or During Receptor Assembly.** To test if the reduction of L-AChR at the NMJ of *emc-6(kr150)* mutants reflected a decrease in total receptor expression, we quantified the amount of the UNC-29 L-AChR subunit by Western blot analysis (Fig. 4A). UNC-29 expression was decreased by 72% in *emc-6(kr150)* compared with the WT. Decreased L-AChR expression could be caused at transcriptional or translational steps. To test if *emc-6* was required for gene expression, we measured the mRNA levels of *unc-29*, *unc-38*, and *unc-63*, the three essential L-AChR subunits, and the mRNA levels of *acr-16* and *unc-49*, the constitutive subunits of homomeric N-AChRs

and GABA<sub>A</sub> receptors, respectively (Fig. S4A and B). Compared with the WT, we did observe a slight but not significant decrease of these receptors' mRNA levels in *emc-6(kr150)* mutants.


To test if EMC-6 was required for L-AChR biosynthesis within the ER, we analyzed the effect of *emc-6* inactivation on un-assembled L-AChR subunits retained in the ER. If EMC-6 is required for the folding or stability of un-assembled L-AChR subunits, impairing *emc-6* function should reduce the level of remaining un-assembled subunits. Conversely, if EMC-6 is required after the assembly of the receptor, we predict that ER-retained un-assembled subunits would not be affected by *emc-6(kr150)* mutation. We have previously demonstrated that L-AChR subunits do not traffic to the plasma membrane when the essential UNC-63 subunit is absent (38). In *unc-63(0)* mutants, un-assembled UNC-29 subunits accumulate in the ER and are readily detected by Western blot (Fig. 4A). In *unc-63(0); emc-6(kr150)* double mutants, the amount of UNC-29 was decreased [compare with *unc-63(0)*] to a similar extent as in *emc-6(kr150)* single mutants (compared with WT) (Fig. 4A), suggesting that *emc-6* is indeed required for the stability of ER-retained un-assembled subunits.

Recently, Rer1, a Golgi-ER retrieval receptor, was demonstrated to control the expression of vertebrate muscle AChRs by ensuring the retention of un-assembled subunits in the ER (47). To test the possibility that EMC-6 might also be involved in the control of the ER exit of receptor subunits, we analyzed the UNC-29 glycosylation profile in *unc-63(0)* and *emc-6(kr150)* (Fig. 4B). Mature N-glycosylations on membrane proteins are resistant to Endoglycosidase H (EndoH) cleavage after trafficking through the secretory pathway, whereas the nascent sugar side chains synthesized in the ER are cleaved by EndoH. By contrast, peptide-N-glycosidase F (PNGase) eliminates all carbohydrates from N-linked glycosylation. To distinguish between mature and immature L-AChRs, we analyzed the digestion profiles of the UNC-29 subunit after treatments by EndoH or PNGase. In the WT, UNC-29 is resistant to EndoH, whereas it is fully sensitive in *unc-63(0)* in agreement with ER retention of the remaining un-assembled L-AChR subunits (the doublet that was observed in the WT likely corresponds to partially glycosylated subunits generated during L-AChR maturation processes, in addition to fully resistant mature species). In *emc-6(kr150)*, the remaining UNC-29 subunits were also resistant to EndoH, similar to the WT, indicating that these subunits were properly matured in the absence of EMC-6. In contrast, UNC-29 was fully sensitive to EndoH in the double mutant *unc-63(0); emc-6(kr150)*, indicating that even in the absence of EMC-6, un-assembled subunits are still retained in the ER.

Altogether, these results suggest that EMC-6 is not involved in the regulation of the ER exit of AChRs and point to a stabilizing role of EMC-6 during receptor subunit maturation and assembly within the ER.

***emc-6* Is a Component of the EMC, a Conserved Complex Required for L-AChR Maturation in *C. elegans*.** In yeast, the EMC-6 ortholog (EMC6p) forms a physical complex with five additional proteins (43). This complex localizes to the ER and was accordingly named the "ER membrane protein complex." Inactivation of this complex triggers ER stress and activation of the UPR pathway. It was also recently linked to the ERAD machinery in human cell lines (48). The EMC members EMC1 to EMC6 are conserved from yeast to humans (Table S1). We tentatively named the *C. elegans* orthologs *emc-1* through *emc-6* (corresponding ORFs are shown in Table S1).

The L-AChR biosynthesis defects in *emc-6(kr150)* might be caused by a global dysfunction of the EMC. Alternatively, the very selective *kr150* mutation might have unmasked a specific contribution of the EMC-6 protein for multimeric transmembrane receptor biosynthesis. To test these hypotheses, we inactivated the *emc-1* through *emc-6* genes by RNAi because no mutations exist




**Fig. 3.** EMC-6 is required for surface expression of ionotropic receptors. (A) Response to pressure ejection of levamisole in voltage-clamped ventral BWMs is reduced in *emc-6(kr150)* [mean ± SEM (WT: 367 ± 37 pA,  $n = 7$ ; *emc-6(kr150)*: 87 ± 8 pA,  $n = 6$ ;  $P = 0.0012$ ]. Arrowheads mark application onset. (B) L-AChR-dependent evoked currents recorded from BWMs after ventral nerve cord stimulation are decreased in *emc-6(kr150)*. Electrically evoked responses were obtained in a *unc-49(e407); acr-16(ok789)* genetic background to eliminate GABA<sub>A</sub> receptor and N-AChR contributions (WT: 553 ± 50 pA,  $n = 6$ ; *emc-6(kr150)*: 210 ± 31 pA,  $n = 6$ ;  $P = 0.0022$ ). (C) L-AChR expression is decreased at NMJs of *emc-6(kr150)* mutants (i, iii, iv, and vi), whereas presynaptic differentiation is unaffected (ii, iii, v, and vi). L-AChRs are labeled using anti-UNC-38. Cholinergic boutons are labeled using an anti-vesicular acetylcholine transporter UNC-17 (VACht) antibody. (Scale bars, 10  $\mu$ m.) (D) Visualization of L-AChRs in living worms using a knock-in UNC-29-tagRFP L-AChR subunit engineered by *MosTIC* homologous recombination. DC, dorsal cord; NR, nerve ring. Arrowheads indicate L-AChR clusters at the dorsal nerve cord. Intestinal autofluorescence is indicated with an asterisk. (Scale bars, 10  $\mu$ m.) (E) UNC-29-tagRFP fluorescence is reduced in *emc-6(kr150)* mutants (WT: 18.1 ± 2.5 arbitrary units,  $n = 14$ ; *emc-6(kr150)*: 2.9 ± 0.3 arbitrary units,  $n = 13$ ;  $***P < 0.001$ , Mann-Whitney test). (F) EMC-6 is required for N-AChR function. Response to pressure ejection of nicotine (WT: 931 ± 78 pA,  $n = 8$ ; *emc-6(kr150)*: 633 ± 94 pA,  $n = 12$ ;  $P = 0.023$ ). Arrowheads mark application onset. (G) EMC-6 is required for GABA<sub>A</sub> receptor function. Response to pressure ejection of GABA (WT: 1552 ± 118 pA,  $n = 6$ ; *emc-6(kr150)*: 710 ± 172 pA,  $n = 5$ ;  $P = 0.0043$ ). Arrowheads mark application onset.

in any of the *C. elegans* EMC member orthologs except for *emc-6(kr150)*. Inactivation of EMC members led to various phenotypic defects, including embryonic lethality and developmental arrest (Table S2). Strikingly, inactivation of *emc-1*, *emc-2*, *emc-3*, *emc-4*, and *emc-6* caused significant resistance to levamisole compared with worms fed with an empty RNAi vector (Fig. 5A). The lack of effect of *emc-5* RNAi might reflect a specific function of EMC-5 in the EMC or heterogeneity of EMC composition according to its substrate.

These data provide indirect support for the existence of an EMC in *C. elegans* and suggest that the entire complex is required to ensure proper maturation of L-AChRs.

**C. elegans EMC Is Involved in ER Homeostasis.** The EMC was identified as a complex involved in ER homeostasis in yeast and in ERAD in human cells. To test if EMC inactivation leads to ER stress in *C. elegans*, we used the UPR reporter *Phsp-4::gfp*, whose expression is strongly induced in the gut and hypodermis by UPR activation (49). Inactivation of *emc-1*, *emc-2*, *emc-3*, *emc-4*, and *emc-6* by RNAi was associated with significant ER stress (Fig. 5B). Inactivation of *emc-5* seemed to have no significant effect on UPR activation. To test whether UPR activation was a side effect of decreased L-AChR function, we inactivated *unc-50* by RNAi and saw no ER stress induction despite strong resistance to levamisole (Fig. 5A and B).



**Fig. 4.** *emc-6* is required before or during L-AChR assembly. (A) L-AChR expression is reduced in *emc-6(kr150)* mutants. Levels of unassembled UNC-29 L-AChR subunits detected in *unc-63(kr13)* are further decreased in *unc-63(0); emc-6(kr150)* double mutants. UNC-29 levels are quantified by Western blot using anti-UNC-29 antibodies and normalized to tubulin levels. The migration profile of UNC-29 subunit appears to be slightly different in *emc-6(kr150)* compared with other genotypes, which might reflect slight changes of UNC-29 glycosylation. Seven independent experiments were quantified (mean  $\pm$  SEM). n.s. (not significant),  $P > 0.05$ ; \* $P < 0.05$ ; \*\* $P < 0.01$  after Holm correction, Mann–Whitney–Wilcoxon test. (B) Remaining L-AChRs exit the ER in *emc-6(kr150)*. Treatments with EndoH or N-Glycosidase F (PNGase) were performed on protein extracts of mixed-stage animals before SDS/PAGE analysis. Black arrowheads indicate glycosylated forms resistant to EndoH, gray arrowheads indicate partially glycosylated forms partially resistant to EndoH, and white arrowheads indicate unglycosylated forms sensitive to EndoH.


Because EMC inactivation caused ER stress, we asked whether the L-AChR biosynthesis defects of *kr150* mutants could be an indirect consequence of ER stress. We therefore tested whether down-regulation or overactivation of the UPR pathway would decrease L-AChR expression. Mutants of the two major components of the UPR pathway in *C. elegans*, *ire-1* and *xbp-1* (49), were fully sensitive to levamisole and had normal levels of L-AChRs at the NMJ based on immunostaining (Fig. S5A and B). Similarly, the *upr-1(zc6)* mutation, which leads to constitutive activation of the UPR pathway (49), did not cause resistance to levamisole. These results demonstrate that *C. elegans* EMC inactivation triggers ER stress and activation of the UPR independent of its role in L-AChR biosynthesis.

## Discussion

A genetic screen for mutants partially resistant to the cholinergic agonist levamisole identified *emc-6*, a previously uncharacterized gene coding for a small transmembrane protein of the ER. Our data show that EMC-6 is cell-autonomously required in muscle cells to ensure the expression of L-AChRs as well as two other multimeric ligand-gated ion channels. It likely functions within the recently identified EMC to stabilize unassembled L-AChR subunits and promote their assembly into mature receptors. More generally, the EMC seems to be essential for the viability of the organism and is required for maintaining ER homeostasis in vivo.

**EMC Is an Evolutionarily Conserved Protein Complex.** *emc-6* is the ortholog of the yeast gene *EMC6*, which was identified in 2009 by Jonikas et al. (43) over the course of a genome-wide identification of genes contributing to protein folding in the ER. Comprehensive analysis of the interactions between these genes identified a functional cluster of six poorly characterized genes subsequently named *EMC1* to *EMC6*. Immunoprecipitation experiments demonstrated that these six proteins form an apparently stoichiometric complex. They are all predicted to be ER resident transmembrane proteins, except for EMC2. This complex was further identified independently by Kopito and colleagues (48) in 2012 in a high-throughput approach combining proteomics and functional genomics to define ERAD networks in human cells. Physical interactors of 25 baits involved in ERAD were identified after protein complex purification and liquid chromatography-tandem MS. Specifically, reciprocal interactions were detected among 10 proteins, including orthologs of the six yeast EMC members. The four additional proteins are not present in yeast but seem to be conserved in *C. elegans* (Table S1). Remarkably, almost nothing is known about the function of these genes, either in yeast or in mammals, and none of these genes have previously been studied in *C. elegans*.

Here, we have characterized EMC-6 and demonstrated that it is an ER protein likely expressed in all tissues. The shared phenotypes observed after inactivation of other *emc* genes suggests that EMC-6 functions together with other EMC members in *C. elegans*. For example RNAi inactivation of *emc-1*, *emc-2*, *emc-4*, or



**Fig. 5.** EMC is required for L-AChR expression and ER homeostasis. (A) EMC inactivation by RNAi leads to resistance to levamisole. Bars represent the percentage of resistant animals after overnight exposure to 0.4 mM levamisole following preembryonic RNAi in *eri-1(mg366)*. Four to 13 independent experiments were performed (20–45 animals per condition per experiment) (mean  $\pm$  SEM). n.s. (not significant),  $P > 0.05$ ; \*\*\* $P < 0.001$  after Holm correction, Mann–Whitney–Wilcoxon test. (B) EMC inactivation triggers the UPR. (i) Representative pictures of young adults expressing GFP under the control of the *hsp-4* promoter reporting the extent of the UPR (intensity: +, white; ++, gray; +++ black). (ii) Bar graph represents UPR in worms exposed to control (empty vector), *emc*, or *unc-50* RNAi. RNAi was performed preembryonically by feeding the parent WT worms with bacteria expressing dsRNA. n, number of animals tested. Four to eight independent experiments were pooled. n.s. (not significant),  $P > 0.05$ ; \*\*\* $P < 0.001$  after Bonferroni correction, Fisher exact test.

*emc-6* causes embryonic lethality or developmental arrest, and inactivation of any *emc* gene except *emc-5* decreased the expression of L-AChRs (Fig. 5A). The phenotypic differences that we observed after inactivating individual *emc* genes might arise for several nonexclusive reasons. First, they might reflect variation of RNAi efficiency for individual *emc* genes and the tissues in which they are expressed (50) because our phenotypic readout is at the organismal level. Second, the EMC might contain core components whose inactivation destabilizes the entire complex and has

more drastic effects than when targeting peripheral components. Third, the composition of the complex might vary according to its substrates. Fourth, it is very likely that individual components contribute specific functions to the whole complex. Testing these different hypotheses will require the detailed characterization of each EMC subunit and the biochemical reconstitution of the complex.

**EMC Requirement for ER Homeostasis Can Be Genetically Dissociated from Specific Functions for Cys-Loop Receptor Biosynthesis.** We showed that disruption of the EMC in *C. elegans* causes induction of the UPR (Fig. 5B). Several lines of evidence suggest that UPR induction in *emc* mutants is a direct consequence of protein maturation defects in the ER. First, EMC inactivation in yeast causes a clear UPR induction related to an accumulation of unfolded protein in the ER (51). Interestingly, Jonikas et al. (43) noticed that in yeast, “the pattern of genetic interactions of strains deleted for EMC members most closely resembled that seen in a strain overexpressing the misfolded transmembrane protein Sec61-2p (a mutated form of the Sec61 translocon) (52) and is similar to the pattern of a strain overexpressing the misfolded transmembrane protein KWS (53).” Second, induction of ER stress and UPR by tunicamycin treatment causes the transcriptional induction of 9 of the 10 EMC members in human cell lines, a typical feature of genes involved in protein folding and degradation (reviewed in ref. 54). Third, *emc* inactivation in *C. elegans* causes developmental defects that are usually not related to constitutive UPR activation (49), indicating that these defects, as well as UPR activation, are likely to be downstream consequences of impairment of ER folding capacity in *emc* mutants.

Whether the EMC is similarly required for all transmembrane proteins or is more specifically involved in the biosynthesis of a subclass of proteins, such as ACh and GABA ionotropic receptors, is difficult to answer. However, we observed that the *emc-6* mutation isolated in our genetic screen does not impair the synthesis of all transmembrane proteins. First, we monitored the expression of the AMPA-like glutamate receptor subunit GLR-1, which assembles into a tetrameric ligand-gated ion channel (55), and we saw no decrease in the *emc-6(kr150)* background compared with the WT (Fig. S64). Second, we analyzed vulval development of animals carrying the *emc-6(kr150)* mutation, which provides indirect access to the functionality of the EGF receptor LET-23, a cell surface glycoprotein with a single transmembrane domain. Decreased activity of *let-23* causes vulval induction defects (56). The lack of vulval defects in *emc-6(kr150)* mutants (Fig. S6B) suggests that the EGF receptor LET-23 is properly expressed. These data do not exclude the likely possibility that EMC-6 is required for the synthesis of other unidentified proteins, yet the *emc-6(kr150)* mutation unmasked some in vivo requirements of EMC-6 that are specific for the biosynthesis of GABA and ACh receptors and that all belong to the same superfamily of proteins called the Cys-loop receptors (reviewed in ref. 57).

**EMC Stabilizes Unassembled Subunits of L-AChR.** We have shown in this work that loss of EMC function decreases L-AChR expression, likely by impairing the stability of unassembled subunits or assembly intermediates in the ER (Fig. 4). Interestingly, our results functionally connect the EMC to ERAD because AChR subunits are established integral-membrane ERAD substrates (23). We propose that the EMC regulates the amount of subunits available to assemble into mature L-AChRs either by behaving as a chaperone for unassembled or partially assembled subunits or by modulating ERAD of AChR subunits.

The best-characterized factors that are known to influence AChR subunit stability in the ER are ER chaperones. In Cos cells and in myotubes, binding of AChR subunits with BIP was proposed to act as a protective pathway to prevent misfolded subunits from altering receptor assembly (58). This hypothesis has been indirectly con-

firmed in *C. elegans*, where the interaction between BIP and un-assembled L-AChR subunits is much stronger than with assembled L-AChRs (59). The calnexin and ERp57 ER-resident component of the biosynthetic machinery also form transient complexes with newly synthesized AChRs before full assembly occurs (17). The association of AChR subunits with ER proteins would decrease the rate of ERAD-dependent subunit degradation (17). By analogy, the EMC might provide a functional chaperone activity to stabilize or enhance the folding of partially assembled AChR subunits.

L-AChRs are the first proteins, to our knowledge, whose synthesis has been demonstrated to depend on EMC activity. The isolation of the *emc-6(kr150)* mutant may have been serendipitous. Alternatively, screening for L-AChR synthesis defects might be a very sensitive assay for EMC activity because of the very inefficient folding of these oligomeric transmembrane proteins. Specifically, AChR subunits contain an amphipathic transmembrane helix, M2, with a series of hydrophilic residues. In mature receptors, the M2 helices from each of the five subunits are organized around a pseudosymmetry axis and form a transmembrane cationic pore. It is not known how the hydrophilic face of the M2 helix of a partially assembled subunit is stabilized in the ER membrane before being buried in mature receptors. This topological issue is shared by all Cys-loop receptors, including the N-AChRs and UNC-49/GABA<sub>A</sub> receptor, which we have demonstrated also depend on the EMC for their synthesis in *C. elegans*. To gain further insight into the role of this complex in the biosynthesis of AChRs, it will be of great interest to identify other “substrates” of the EMC and test if the EMC indeed behaves as a chaperone for additional transmembrane proteins.

## Materials and Methods

**General Methods and Strains.** Unless indicated otherwise, strains were maintained at 20 °C on nematode growth medium (NGM) agar plates under standard conditions. OP50 *Escherichia coli* was generally used for feeding, except for strains exposed to RNAi, which were maintained on 1-mM isopropyl- $\beta$ -D-thiogalactopyranoside (IPTG) plates with HT115 for feeding. The WT reference strain was N2 Bristol. Strains, molecular constructs, transgenes, and primers are described in *SI Materials and Methods*.

**Levamisole Assay.** Assays for levamisole sensitivity after overnight exposure were performed as previously described (60). Further details are provided in *SI Materials and Methods*.

**Electrophysiology.** Electrophysiological methods were as previously described by Richmond and Jorgensen (30) and Gendrel et al. (60). L-AChR evoked recording analysis was performed in a *unc-49(e407); acr-16(ok789)* background to eliminate currents arising from activation of GABA<sub>A</sub> receptors and N-AChRs.

**Immunocytochemical Staining.** Worms were prepared by the freeze-crack method described previously (60). Further details are provided in *SI Materials and Methods*.

**Western Blotting.** Mixed-stage populations were collected from OP50-seeded NGM plates. They were rinsed three times with water and allowed to sedi-

ment on ice to wash out bacteria. Pellets were solubilized in Laemmli buffer with 2% (vol/vol)  $\beta$ -mercaptoethanol, boiled at 90 °C for 10 min, sonicated for 1 min, and centrifuged for 5 min at 15,700  $\times$  g. For glycosylation profiles, samples were treated with denaturation buffer for 10 min at 90 °C, incubated with endoglycosidase H (EndoH; New England Biolabs) or PNGaseF (New England Biolabs) for 1 h at 37 °C, and subsequently treated with Laemmli buffer as described above. Membranes were imaged with a LAS4000 (GE Healthcare Life Sciences) luminescence detector and band intensity-quantified with LAS4000 software. Further details are provided in *SI Materials and Methods*.

**Isolation of RNA and Quantitative Real-Time PCR Assay.** Synchronized first-stage larval (L1) cultures were obtained by treating young gravid adults with a bleaching solution for 5 min. Surviving eggs were allowed to reach the L1 stage during an overnight immersion in M9 solution. Total RNA was isolated from this synchronized population using the RNeasy Kit (Qiagen) according to the manufacturer's instructions. All samples were treated with DNase (Fermentas). First-strand cDNA was synthesized from 200 ng of total RNA using an oligo(dT) primer and a Moloney murine leukemia virus reverse transcriptase (Fermentas) at 42 °C for 1 h. Quantitative PCR was performed using Light-Cycler 480 SYBR Green I Master (Roche). Primer sequences are listed in *SI Materials and Methods*. A relative quantification model, including kinetic PCR efficiency correction, was used to evaluate the relative expression ratio of the target genes (61). RNA levels were normalized to the three housekeeping genes *cdc-42*, *pmp-3*, and *Y45F10D.4* according to the method of Hoogewijs et al. (62). Further details are provided in *SI Materials and Methods*.

**RNAi.** RNAi was performed using the bacterial feeding protocol (63) with the following modifications. NGM agar plates containing 1 mM IPTG and 100  $\mu$ g/mL ampicillin were seeded with bacteria expressing dsRNA. L4-staged hermaphrodites were placed onto these plates and grown at 20 °C. After 4 d, the F1 progeny of these worms were scored for phenotypes of interest. If not available in the library of Kamath and Ahringer (63), PCR was used to amplify fragments flanked by the T7 promoter at the 5' and 3' ends. Further details are provided in *SI Materials and Methods*.

**Light Microscopy and Fluorescence Quantification.** For surface AChR quantification, animals were anesthetized with M9 buffer containing 100 mM sodium azide mounted on 2% (wt/vol) agarose in M9 pads and examined by epifluorescence using a Nikon macrozoom microscope equipped with a chilled CCD camera (stress induction) or a Leica DM5000B microscope with a spinning disk. Images were acquired using METAMORPH 7.1 software (Molecular Devices) and analyzed with IMAGEJ software (National Institutes of Health).

**ACKNOWLEDGMENTS.** We thank L. Pintard, M. Labouesse, and E. Chevet for critical reading of the manuscript. We thank L. Briseño-Roa and M. Barkoulas for technical advice. We thank the Caenorhabditis Genetic Center and the International *C. elegans* Gene Knock-Out Consortium for strains. We thank T. Hoppe, M. Calfon, L. Pintard, and M.-A. Felix for critical reagents. M.R. was supported by the Neuropole francilien and by the Association pour la Recherche contre le Cancer. This work was funded by the Institut National de la Santé et de la Recherche Médicale (V.J.P.R. and J.-L.B.), the European Molecular Biology Organization (T.B.), the Centre National de la Recherche Scientifique (T.B.), Grant MH073156 from the National Institutes of Health (to J.E.R.), and the Association Française contre les Myopathies and Fondation pour la Recherche Médicale (J.-L.B.).

1. Millar NS, Gotti C (2009) Diversity of vertebrate nicotinic acetylcholine receptors. *Neuropharmacology* 56(1):237–246.
2. Gorrie GH, et al. (1997) Assembly of GABA<sub>A</sub> receptors composed of alpha1 and beta2 subunits in both cultured neurons and fibroblasts. *J Neurosci* 17(17):6587–6596.
3. Jensen TJ, et al. (1995) Multiple proteolytic systems, including the proteasome, contribute to CFTR processing. *Cell* 83(1):129–135.
4. Merlie JP, Lindstrom J (1983) Assembly in vivo of mouse muscle acetylcholine receptor: Identification of an alpha subunit species that may be an assembly intermediate. *Cell* 34(3):747–757.
5. Arroyo-Jimenez MM, et al. (1999) Ultrastructural localization of the alpha4-subunit of the neuronal acetylcholine nicotinic receptor in the rat substantia nigra. *J Neurosci* 19(15):6475–6487.
6. Sabatelli M, et al. (2009) Rare missense variants of neuronal nicotinic acetylcholine receptor altering receptor function are associated with sporadic amyotrophic lateral sclerosis. *Hum Mol Genet* 18(20):3997–4006.
7. Richards CI, et al. (2011) Trafficking of alpha4\* nicotinic receptors revealed by superreleptin phluorin: Effects of a beta4 amyotrophic lateral sclerosis-associated mutation and chronic exposure to nicotine. *J Biol Chem* 286(36):31241–31249.
8. Srinivasan R, et al. (2012) Pharmacological chaperoning of nicotinic acetylcholine receptors reduces the endoplasmic reticulum stress response. *Mol Pharmacol* 81(6):759–769.
9. Sallette J, et al. (2005) Nicotine upregulates its own receptors through enhanced intracellular maturation. *Neuron* 46(4):595–607.
10. Govind AP, Walsh H, Green WN (2012) Nicotine-induced upregulation of native neuronal nicotinic receptors is caused by multiple mechanisms. *J Neurosci* 32(6):2227–2238.
11. Rezvani K, Teng Y, Shim D, De Biasi M (2007) Nicotine regulates multiple synaptic proteins by inhibiting proteasomal activity. *J Neurosci* 27(39):10508–10519.
12. Millar NS, Harkness PC (2008) Assembly and trafficking of nicotinic acetylcholine receptors (Review). *Mol Membr Biol* 25(4):279–292.
13. Blount P, Merlie JP (1991) BIP associates with newly synthesized subunits of the mouse muscle nicotinic receptor. *J Cell Biol* 113(5):1125–1132.
14. Paulson HL, Ross AF, Green WN, Claudio T (1991) Analysis of early events in acetylcholine receptor assembly. *J Cell Biol* 113(6):1371–1384.
15. Gelman MS, Chang W, Thomas DY, Bergeron JJ, Prives JM (1995) Role of the endoplasmic reticulum chaperone calnexin in subunit folding and assembly of the nicotinic acetylcholine receptors. *J Biol Chem* 270(25):15085–15092.



16. Wanamaker CP, Green WN (2005) N-linked glycosylation is required for nicotinic receptor assembly but not for subunit associations with calnexin. *J Biol Chem* 280(40):33800–33810.
17. Wanamaker CP, Green WN (2007) Endoplasmic reticulum chaperones stabilize nicotinic receptor subunits and regulate receptor assembly. *J Biol Chem* 282(43):31113–31123.
18. Green WN, Wanamaker CP (1997) The role of the cystine loop in acetylcholine receptor assembly. *J Biol Chem* 272(33):20945–20953.
19. Gehle VM, Walcott EC, Nishizaki T, Sumikawa K (1997) N-glycosylation at the conserved sites ensures the expression of properly folded functional ACh receptors. *Brain Res Mol Brain Res* 45(2):219–229.
20. Drisdell RC, Manzana E, Green WN (2004) The role of palmitoylation in functional expression of nicotinic alpha7 receptors. *J Neurosci* 24(46):10502–10510.
21. Wanamaker CP, Christianson JC, Green WN (2003) Regulation of nicotinic acetylcholine receptor assembly. *Ann N Y Acad Sci* 998:66–80.
22. Wang J-M, et al. (2002) A transmembrane motif governs the surface trafficking of nicotinic acetylcholine receptors. *Nat Neurosci* 5(10):963–970.
23. Christianson JC, Green WN (2004) Regulation of nicotinic receptor expression by the ubiquitin-proteasome system. *EMBO J* 23(21):4156–4165.
24. Srinivasan R, et al. (2011) Nicotine up-regulates alpha4beta2 nicotinic receptors and ER exit sites via stoichiometry-dependent chaperoning. *J Gen Physiol* 137(1):59–79.
25. Keller SH, Lindstrom J, Ellisman M, Taylor P (2001) Adjacent basic amino acid residues recognized by the COP I complex and ubiquitination govern endoplasmic reticulum to cell surface trafficking of the nicotinic acetylcholine receptor alpha-Subunit. *J Biol Chem* 276(21):18384–18391.
26. Ren X-Q, et al. (2005) Structural determinants of alpha4beta2 nicotinic acetylcholine receptor trafficking. *J Neurosci* 25(28):6676–6686.
27. Jeanclos EM, et al. (2001) The chaperone protein 14-3-3beta interacts with the nicotinic acetylcholine receptor alpha 4 subunit. Evidence for a dynamic role in subunit stabilization. *J Biol Chem* 276(30):28281–28290.
28. Rezvani K, et al. (2009) UBXD4, a UBX-containing protein, regulates the cell surface number and stability of alpha3-containing nicotinic acetylcholine receptors. *J Neurosci* 29(21):6883–6896.
29. Jones AK, Sattelle DB (2004) Functional genomics of the nicotinic acetylcholine receptor gene family of the nematode, *Caenorhabditis elegans*. *Bioessays* 26(1):39–49.
30. Richmond JE, Jorgensen EM (1999) One GABA and two acetylcholine receptors function at the *C. elegans* neuromuscular junction. *Nat Neurosci* 2(9):791–797.
31. Lewis JA, Wu CH, Berg H, Levine JH (1980) The genetics of levamisole resistance in the nematode *Caenorhabditis elegans*. *Genetics* 95(4):905–928.
32. Fleming JT, et al. (1997) *Caenorhabditis elegans* levamisole resistance genes *lev-1*, *unc-29*, and *unc-38* encode functional nicotinic acetylcholine receptor subunits. *J Neurosci* 17(15):5843–5857.
33. Touroutine D, et al. (2005) *acr-16* encodes an essential subunit of the levamisole-resistant nicotinic receptor at the *Caenorhabditis elegans* neuromuscular junction. *J Biol Chem* 280(29):27013–27021.
34. Francis MM, et al. (2005) The Ror receptor tyrosine kinase CAM-1 is required for ACR-16-mediated synaptic transmission at the *C. elegans* neuromuscular junction. *Neuron* 46(4):581–594.
35. Halevi S, et al. (2002) The *C. elegans ric-3* gene is required for maturation of nicotinic acetylcholine receptors. *EMBO J* 21(5):1012–1020.
36. Boulin T, et al. (2008) Eight genes are required for functional reconstitution of the *Caenorhabditis elegans* levamisole-sensitive acetylcholine receptor. *Proc Natl Acad Sci USA* 105(47):18590–18595.
37. Jospin M, et al. (2009) A neuronal acetylcholine receptor regulates the balance of muscle excitation and inhibition in *Caenorhabditis elegans*. *PLoS Biol* 7(12):e1000265.
38. Alexander JK, et al. (2010) Ric-3 promotes alpha7 nicotinic receptor assembly and trafficking through the ER subcompartment of dendrites. *J Neurosci* 30(30):10112–10126.
39. Eimer S, et al. (2007) Regulation of nicotinic receptor trafficking by the transmembrane Golgi protein UNC-50. *EMBO J* 26(20):4313–4323.
40. Almedom RB, et al. (2009) An ER-resident membrane protein complex regulates nicotinic acetylcholine receptor subunit composition at the synapse. *EMBO J* 28(17):2636–2649.
41. Rapti G, Richmond J, Bessereau J-L (2011) A single immunoglobulin-domain protein required for clustering acetylcholine receptors in *C. elegans*. *EMBO J* 30(4):706–718.
42. Boulin T, et al. (2012) Positive modulation of a Cys-loop acetylcholine receptor by an auxiliary transmembrane subunit. *Nat Neurosci* 15(10):1374–1381.
43. Jonikas MC, et al. (2009) Comprehensive characterization of genes required for protein folding in the endoplasmic reticulum. *Science* 323(5922):1693–1697.
44. Labrousse AM, Zappaterra MD, Rube DA, van der Bliek AM (1999) *C. elegans* dynamin-related protein DRP-1 controls severing of the mitochondrial outer membrane. *Mol Cell* 4(5):815–826.
45. Rolls MM, Hall DH, Victor M, Stelzer EH, Rapoport TA (2002) Targeting of rough endoplasmic reticulum membrane proteins and ribosomes in invertebrate neurons. *Mol Biol Cell* 13(5):1778–1791.
46. Robert V, Bessereau J-L (2007) Targeted engineering of the *Caenorhabditis elegans* genome following Mos1-triggered chromosomal breaks. *EMBO J* 26(1):170–183.
47. Valkova C, et al. (2011) Sorting receptor Rer1 controls surface expression of muscle acetylcholine receptors by ER retention of unassembled alpha-subunits. *Proc Natl Acad Sci USA* 108(2):621–625.
48. Christianson JC, et al. (2012) Defining human ERAD networks through an integrative mapping strategy. *Nat Cell Biol* 14(1):93–105.
49. Calton M, et al. (2002) IRE1 couples endoplasmic reticulum load to secretory capacity by processing the XBP-1 mRNA. *Nature* 415(6867):92–96.
50. Simmer F, et al. (2003) Genome-wide RNAi of *C. elegans* using the hypersensitive *rrf-3* strain reveals novel gene functions. *PLoS Biol* 1(1):E12.
51. Nakatsukasa K, Brodsky JL (2008) The recognition and retrotranslocation of misfolded proteins from the endoplasmic reticulum. *Traffic* 9(6):861–870.
52. Sommer T, Jentsch S (1993) A protein translocation defect linked to ubiquitin conjugation at the endoplasmic reticulum. *Nature* 365(6442):176–179.
53. Vashist S, Ng DTW (2004) Misfolded proteins are sorted by a sequential checkpoint mechanism of ER quality control. *J Cell Biol* 165(1):41–52.
54. Ron D, Walter P (2007) Signal integration in the endoplasmic reticulum unfolded protein response. *Nat Rev Mol Cell Biol* 8(7):519–529.
55. Maricq AV, Peckol E, Driscoll M, Bargmann CI (1995) Mechanosensory signalling in *C. elegans* mediated by the GLR-1 glutamate receptor. *Nature* 378(6552):78–81.
56. Ferguson EL, Sternberg PW, Horvitz HR (1987) A genetic pathway for the specification of the vulval cell lineages of *Caenorhabditis elegans*. *Nature* 326(6110):259–267.
57. Sine SM, Engel AG (2006) Recent advances in Cys-loop receptor structure and function. *Nature* 440(7083):448–455.
58. Forsayeth JR, Gu Y, Hall ZW (1992) BiP forms stable complexes with unassembled subunits of the acetylcholine receptor in transfected COS cells and in C2 muscle cells. *J Cell Biol* 117(4):841–847.
59. Gottschalk A, et al. (2005) Identification and characterization of novel nicotinic receptor-associated proteins in *Caenorhabditis elegans*. *EMBO J* 24(14):2566–2578.
60. Gendrel M, Rapti G, Richmond JE, Bessereau J-L (2009) A secreted complement-control-related protein ensures acetylcholine receptor clustering. *Nature* 461(7266):992–996.
61. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. *Nucleic Acids Res* 29(9):e45.
62. Hoogewijs D, Houthoofd K, Matthijssens F, Vandesompele J, Vanfleteren JR (2008) Selection and validation of a set of reliable reference genes for quantitative sod gene expression analysis in *C. elegans*. *BMC Mol Biol* 9:9.
63. Kamath RS, Ahringer J (2003) Genome-wide RNAi screening in *Caenorhabditis elegans*. *Methods* 30(4):313–321.

# Supporting Information

Richard et al. 10.1073/pnas.1216154110

## SI Materials and Methods

**General Methods and Strains.** The WT strain N2 and the following mutant alleles were used: *emc-6(kr150)*, *acr-16(ok789)*, *unc-49(e407)*, *unc-29(kr208::tagRFP)*, *unc-29(x29)* as *unc-29* null allele, *unc-63(kr13)* as *unc-63* null allele, *nra-2(tm1453)*, *nra-4(hd127)*, *nuIs24(P<sub>glr-1</sub>GLR-1::GFP)*, *nDf29/unc-13(e1091am) lin-11(n566)*, *nDf23/unc-13(e1091am) lin-11(n566)*, *eri-1(mg366) zcIs4 [Phsp-4::GFP]*, *unc-119(ed4) III*; *hhIs64[unc-119(+);sur-5::UbiV-GFP]*, *ire-1(v33)*, *xbp-1(zc12)*, and *upr-1(zc6)*.

The following transgenic lines were generated:

Integrated transgene in N2: *krIs56 [Pmyo3::HA::Ce-emc6 (pMR41); Pmyo2::GFP, Pmyo3::GFP]*. Integration was performed by means of irradiation.

Extrachromosomal array in *emc-6(kr150)*: *krEx414–416 [oTB398-oTB329 PCR gDNA *Caenorhabditis elegans*, Pmyo-2::gfp, Pmyo-3::gfp]*, *krEx821–822 [oTB398-oTB328 PCR fragment of Pmyo3::emc-6 (pMR08), Pmyo2::GFP, Pmyo3::GFP]*, *krEx1059 [PCe-emc-6::GFP (pMR53), rol-6(su1006), panneuronal DsRed2 (pCB101)]*, *krEx1025–1027 [oMR157-oMR158 PCR gDNA *Caenorhabditis briggsae* (AF16), Pmyo2::GFP, Pmyo-3::gfp]*, *krEx1023 [PCb-emc-6::NLS-GFP (pMR63), rol-6(su1006), panneuronal DsRed2 (pCB101)]*, and *krEx1047–1048 [Pmyo3::GFP::Cb-emc-6 (pMR65), Pmyo3::tagRFP-T::KDEL (pMR68), Pmyo2::GFP]*

Extrachromosomal array in *krIs56*: *krEx967 [Pmyo3::MANS::tagRFP-T (pMR61), rol-6(su1006), panneuronal DsRed2 (pCB101)]*

**C. elegans Germline Transformation.** Transformation was performed by microinjection of DNA mixture in the gonad of young adults. The total DNA concentration of the injection mix was normalized at 100 ng/μL using 1kb+ ladder (Invitrogen).

The following PCR fragments were used for *C. elegans* germline transformation: *ttcagatataaaagcgagcaaa (oTB398)/tcgaacaacgataacatcctg (oTB329)* and *cgaaatcgcagacattggt (oMR157)/tcaagctctttacgctcgt (oMR158)*.

The following plasmids were used for *C. elegans* germline transformation:

*pMR08*: PCR fragment *AAAGGTACCAAATGTCCGATAAATCGTCAAA (oMR46)/ATACCATGGAAGCTGGATTGATTTATTAAT (oMR39)* from *emc-6* cDNA cloned into pPD95.86 by NcoI and KpnI

*pMR41*: Amplification of *HA::emc-6* by *cgccaacatgttctttttgatattagttattgttaatttcagatttcaaatgTACGTATaccatagcagctccagactacgctAGATCTccgataaatcgtaaacgag (oMR53)* and *aaaggtacctcagatatacgaaccattccg (oMR43)* from *C. elegans* (N2) gDNA cloned into pPD95.86.

*pMR53*: PCR fragment *cccCTGCAGttcagatataaaagcgagcaaa (oMR100)/cccGGATCCttaaattcgaattacaaat (oMR101)* from *C. elegans* (N2) gDNA cloned into L4054 by BamHI/PstI

*pMR61*: *Pmyo3* cloned by PstI/NotI from L4037 and tagRFP-T cloned by MluI/NheI into *Pglr-1::YFP::MANS* (gift of M. Rolls, Pennsylvania State University, University Park, PA)

*pMR63*: PCR fragment *cccCTGCAGctgaaattcattttttta (oMR159)/cccGGATCCttccaggctgaaatataag oMR160* from *C. briggsae* (AF16) gDNA cloned into L4054 by BamHI/PstI

*pMR65*: Isothermal ligation of pPD95.86 digested KpnI/SacI with *gtatgttccgaatgataacataacatagaacattttcagGAGGACCCT-TGGCTAGCGTCGACGGTACCatgTACGTAgtagcaagggc-gagga (oMR169)/actcgtgtttttcttccgttttcgacgacttctactagatc-tctgtacagctcgtccat (oMR162) eGFP fragment and agtgagaa-gtcgtcgaacaggagaa (oMR163)/CGGGCGCGAGATGGCG-ATCTGATGACAGCGGCCGATGCGGAGCTCttaatatacat-gtaccattc (oMR170) Cb-emc6 fragment*

*pMR68*: Amplification of *tagRFP::KDEL(aaagatgaact)::* by *gggGCTAGCAAAAATGCATAAGGTTTTGCTGGCACTG-TTCTTTATCTTTCTGGCACCAGCATCCGCACTGGCAG-TCTCCGAACCGTCTCTAGCGTCGACGGTACCGGTAG-AAAAAATGGTGTCTAAGGCGGAAGAGCT (oMR175)/gggCCATGGTTAAAGTTCATCTTTTCTAGATCCGGTGG-ATCCCGGG (oMR176) tagRFP KDEL(aaagatgaact)::* cloned into pPD95.86 by NcoI/NheI

**Levamisole Assay.** (–)-Tetramisole hydrochloride (Sigma) was dissolved in water and added to 55 °C-equilibrated nematode growth medium (NGM) agar at a concentration of 0.4 mM or 0.6 mM just before plates were poured. Levamisole-containing plates were seeded with OP50 *Escherichia coli*. Young adult worms were put on plates containing levamisole, animals were left overnight at 20 °C, and surviving animals were then scored. Plates with 0.6 mM levamisole were used for rescue experiments.

**Immunocytochemical Staining.** Methanol/acetone fixation was used for all staining conditions. The antibodies were used at the following dilutions: mouse anti-UNC-17 (1:3,000; gift of J. Rand, Oklahoma Medical Research Foundation, Oklahoma City), rabbit anti-UNC-38 (1:800; custom antibody), rat anti-HA (1:200; Roche Diagnostics), and rabbit anti-tagRFP (1:500; Evrogen). The secondary antibodies were used at the following dilutions: Cy3-labeled goat anti-rabbit (1:1,000; Jackson ImmunoResearch Laboratories), A488-labeled goat anti-mouse (1:500; Molecular Probes), and A488-labeled goat anti-rat (1:1,000; Molecular Probes). When used for single labeling experiments, antibodies were incubated overnight at 4 °C. In double labeling experiments, incubation conditions were the following: anti-UNC-38 overnight at 4 °C, anti-UNC-17 for 1 h at room temperature, anti-HA overnight at 4 °C, and anti-tagRFP for 1 h at room temperature. Secondary antibodies were incubated together for 3 h at room temperature.

**Western Blotting.** Western blot membranes were probed with affinity-purified rabbit antibody anti-UNC-29 (1:1,000 dilution; custom antibody), mouse commercial antibody anti-TUBULIN (1:1,000 dilution; Sigma), commercial anti-GFP mouse antibody (JL8; 1:1,000 dilution; Sigma), and secondary HRP-conjugated goat anti-rabbit or goat anti-mouse antibody (1:50 dilution; DAKO) and revealed with LumiLight reagents (Roche).

**Isolation of RNA and Quantitative Real-Time PCR Assay.** The following primers were used to amplify target genes:

*cdc-42*: *oMR106 (ctgctggacaggaagattacg)/oMR107 (ctcggacattc-tcgaatgaag)*

*pmp-3*: *oMR108 (gttccctgttcatcactcat)/oMR109 (acaccgtcga-gaagctgtaga)*

*Y45F10D.4*: *oMR110 (gtcgttcaaatcagttcage)/oMR111 (gttctgt-caagtatccgaca)*

*emc-6*: oMR120 (TTGGAAGAACGTGTCAGTTCG)/oMR121 (CCGGAAAGTAGCTCAACCAG)

*unc-29* oMR122 (ggaccaaccgactatcatgg)/oMR123 (aatttcgga-ctggctgaatg)

*unc-63* oMR132 (CTGCTCCTCTCTCCACCAAC)/oMR133 (CCACGAGTGTCTCTCCGTTT)

*acr-16* oMR138 (acggagaatgggctttacct)/oMR139 (aagagttcg-cctctcatgt)

*unc-38* oMR142 (GCAATGGTCCTTGATCGACT)/oMR143 (GGCTGGACGATACTGCAAAT)

*unc-49* oMR149 (AGACCCTCGACTAGCCTTCG)/oMR150 (CCGACGGTAAGTGAGTTCGAT)

*F22D4.5*: oMR155 (ggcgtaaagagcggtgaag)/oMR156 (ttgttt-ctggctcccttt)

**RNAi.** The following RNAi clones from the library of Kamath and Ahringer (1) were used: *emc-1* (II-1J18), *emc-2* (II-1F24), and *unc-50* (III-5D19). The RNAi clones *pos-1* (V-6A23) and *unc-22* (IV-6K06) were used as controls for RNAi efficiency.

1. Kamath RS, Ahringer J (2003) Genome-wide RNAi screening in *Caenorhabditis elegans*. *Methods* 30(4):313–321.

The following plasmids were constructed:



pMR27 (*emc-6* RNAi): Cloning of *emc-6* cDNA from pMR05 *emc-6* cDNA into ZeroBlunt plasmid (Invitrogen) into L4440 by SpeI/PstI

pMR28 (*F33D4.5* RNAi): CCCactagtGGCGTAAAA-GAGCGTTGAAG (oMR62)/AAActgcagGTGCAGGAT-TACGATGAGCA (oMR63) cloned into L4440 SpeI/PstI


pMR51 (*emc-4* RNAi): PCR fragment CCCactagtGC-CAGGCTTCTACTCGACAG (oMR93)/cccCTGCAGtacaat-gaaatgggggaacg (oMR94) from genomic DNA cloned into L4440 by SpeI/PstI

pMR52 (*emc-3* RNAi): PCR fragment CCCactagtTTTTCC-TACCGATCGTTCGTC (oMR98)/CCCctgcagGTCACGAAT-CCGGAGAATGT (oMR99) from genomic DNA cloned into L4440 by SpeI/PstI

pMR77 (*emc-5* RNAi): PCR fragment cccACTAGTgtttctg-gaacacggcagtt (oMR209)/cccCTGCAGggcgtagtagcgaattg-ga (oMR210) from genomic DNA cloned into L4440 by SpeI/PstI




**Fig. S1.** Characterization of the *kr150* mutation. (A) Alternative *emc-6* mRNA is detected by RT-PCR in *emc-6*(*kr150*). The *Mos1* insertion in *kr150* is located in the last codon before the STOP codon of *emc-6*. An in-frame STOP codon and a cryptic polyadenylation site are present within the *Mos1* sequence. (B) *emc-6* mRNA levels are dramatically decreased in *emc-6*(*kr150*). Quantitative real-time PCR measurements of *emc-6* mRNA level in animals synchronized at the L2 or L4 larval stage. Fold change  $\pm$  SEM is shown in four independent experiments.  $**P < 0.01$ , Mann–Whitney–Wilcoxon test.




**B**

	Resistance to 0.6mM LEV O/N	Embryonic lethality (%)	Adult % (at day 5 of dvpt)	Brood size (at day 5 of dvpt)	L2/L3 arrest (%)
Wild type	No	1.1 ± 1.5 (N = 13)	97.2 ± 2.9 (N = 4)	242.1 ± 3.4 (N = 8)	ND
<i>emc-6(kr150)</i>	Yes	13.3 ± 9.9 (N = 13)	37.9 ± 7.4 (N = 4)	106 ± 54.0 (N = 8)	ND
<i>emc-6(kr150); Ex(gDNA emc-6)</i>	No	ND	ND	ND	ND
<i>emc-6(kr150)/stDf7</i>	ND	100	ND	ND	ND
<i>control RNAi</i>	ND	0.8 ± 18.6 (N = 4)	99.8 ± 0.3 (N = 4)	229 ± 21 (N = 5)	ND
<i>emc-6 RNAi</i>	ND	9.6 ± 13.7 (N = 4)	38.4 ± 23 (N = 4)	125.5 ± 18.2 (N = 5)	ND
<i>F33D4.5 RNAi</i>	ND	58 ± 2.5 (N = 4)	10.3 ± 2.4 (N = 4)	56.8 ± 9.4 (N = 5)	82.9 ± 9.5 (N = 4)


**Fig. S2.** Systematic analysis of the *emc-6* genomic locus. (A) Schematic representation of the *emc-6* genomic locus. (B) Table of phenotypes associated with various down-regulation manipulations of the *emc-6* locus. The *kr150* mutation leads to several phenotypes, including levamisole resistance, embryonic lethality, developmental retardation, and reduction of brood size. *emc-6(kr150)* levamisole resistance can be rescued by expressing the genomic sequence of *emc-6*. The rescue of embryonic lethality, developmental timing, and brood size reduction could not be scored in *emc-6(kr150);Ex(gDNA emc-6)* because injection of the *Ex(gDNA emc-6)* transgene caused partial embryonic lethality and significant developmental defects. Heterozygous animals containing the *kr150* mutation placed over the *stDf7* deficiency, which deletes a large genomic region containing *emc-6*, died early during embryogenesis. The interpretation of these results must be cautious because *emc-6* is the upstream gene of an operon composed of two ORFs, *emc-6* and *F33D4.5*. In *emc-6(kr150)*, *F33D4.5* mRNA levels are also significantly decreased ( $44 \pm 11\%$  at the L2 stage and  $33 \pm 3\%$  at the L4 stage, relative to WT). It is possible that a further reduction of *F33D4.5* in *kr150/stDf7* animals might contribute to embryonic lethality because *F33D4.5* RNAi causes significant embryonic lethality by itself ( $58 \pm 2.5$ , mean  $\pm$  SEM;  $n = 4$ ). We therefore performed specific RNAi against *emc-6* and observed a phenocopy of the *kr150* mutation, which links the phenotypic defects observed in *kr150* mutants to decreased *emc-6* activity. Because *emc-6* RNAi by feeding phenocopies *emc-6(kr150)* phenotypes and *F33D4.5* RNAi by feeding leads to L2/L3 developmental arrest, the *F33D4.5* mRNA level decrease in *emc-6(kr150)* is likely to be aphenotypic. N, number of trials; ND, not determined; qRT-PCR, quantitative RT-PCR.




**Fig. S3.** *emc-6* is likely to be ubiquitously expressed. (A) GFP is expressed under the control of the *C. elegans emc-6* promoter. Pictures of mosaic animals (i-vii) are presented because stable expression of the construct is lethal due to the toxicity of the *emc-6* promoter. (B) Expression of the *C. briggsae* genomic sequence of *emc-6* (*Cb-emc-6*) is sufficient to rescue the *emc-6(kr150)* mutation in *C. elegans*. Gray bars illustrate the percentage of dead animals after overnight exposure to 0.6 mM levamisole, and black bars illustrate the percentage of surviving animals. n, number of animals tested. Three independent lines expressing the *Cb-emc-6* genomic locus were tested. \*\*\* $P < 0.001$ , Fisher exact probability test. (C) Nuclear GFP is expressed in *C. elegans* under the control of the *C. briggsae emc-6* promoter region. *Cb-emc-6* is expressed in every tissue during all developmental stages. I, intestine; H, hyperdermis; M, muscle; NLS, nuclear localization signal; NS, nervous system. (Scale bar, 10  $\mu$ m.)



**Fig. 54.** Transcription of ionotropic receptor subunits is not significantly decreased in *emc-6(kr150)*. (A) Quantitative real-time PCR measurements of mRNA levels for heteromeric levamisole-sensitive AChR (L-AChR; *unc-29*, *unc-63*, and *unc-38*), homomeric nicotine-sensitive AChR (N-AChR; *acr-16*), and GABA<sub>A</sub> receptor (*unc-49*). mRNA samples were collected from synchronized L4 larvae. Fold-change mean  $\pm$  SEM in *emc-6(kr150)* relative to WT is shown in six independent experiments. n.s. (not significant),  $P > 0.05$  after Holm correction, Mann–Whitney–Wilcoxon test. (B) To determine if a partial mRNA level decrease might account for partial levamisole resistance, we quantified *unc-29* mRNA levels in heterozygous animals containing a deletion of one *unc-29* allele. (i) Quantitative real-time PCR measurements of *unc-29* mRNA in synchronized L4 larvae. Fold change in *unc-29*( $\pm$ ) relative to WT (mean = 55.25%). As expected, an  $\sim$ 50% decrease in *unc-29* mRNA level was observed in *unc-29(+)*/*unc-29(0)* animals. (ii) Unlike *kr150* mutants, *unc-29(+)*/*unc-29(0)* animals were fully sensitive to levamisole, which indicates that levamisole resistance in *emc-6(kr150)* is not simply explained by a reduction of L-AChR subunit transcription. Gray bars illustrate the percentage of dead animals after overnight exposure to 0.6 mM levamisole, and black bars illustrate the percentage of surviving animals. n, number of animals tested. Despite no statistical significance, the trend of AChR subunits to being reduced could be explained by activation of endoplasmic reticulum stress in *emc-6* mutants, which would affect the overall level of mRNA transcription.



**Fig. S5.** Unfolded protein response (UPR) perturbation does not induce heteromeric levamisole-sensitive AChR (L-AChR) expression defects. (A) Inactivation of *ire-1* and *xpb-1* has no effect on postsynaptic L-AChR (anti-UNC-38) or presynaptic cholinergic boutons [anti-vesicular acetylcholine transporter UNC-17 (VAcHT)]. (Scale bars, 10  $\mu$ m.) (B) Levamisole resistance is not induced by UPR overactivation or down-regulation. *upr-1(zc6)*, *ire-1(v33)*, and *xpb-1(zc12)* mutants are fully sensitive to overnight exposure to 0.6 mM levamisole. Gray bars illustrate the percentage of dead animals after overnight exposure to 0.6 mM levamisole, and black bars illustrate the percentage of surviving animals ( $n > 60$  animals).



**Fig. S6.** *emc-6(kr150)* does not affect the expression of glutamate and EGF receptors. (A) GLR-1::GFP expression is WT in *emc-6(kr150)*. Young adults carrying an integrated *nuls24(Pglr-1::glr-1::gfp)* array were imaged. Pixel intensity was measured in the anterior portion of the ventral nerve cord of *nuls24* homozygous ( $n = 34$  animals), *nuls24* heterozygous ( $n = 29$  animals), and *nuls24; emc-6(kr150)* mutants ( $n = 23$  animals). n.s. (not significant),  $P > 0.05$ ; \* $P < 0.05$ , Mann-Whitney test. (B) *emc-6(kr150)* does not affect the development of the vulva, which indicates that the EGF receptor *let-23* is expressed at WT level in *emc-6* mutants. (i and ii) Two representative examples of Nomarski images of the vulva in *emc-6(kr150)* mutants ( $n = 31$  animals screened).

**Table S1. Conservation of endoplasmic reticulum membrane complex components**

<i>Saccharomyces cerevisiae</i>	<i>Caenorhabditis elegans</i>	<i>Drosophila melanogaster</i>	<i>Homo sapiens</i>
EMC1p	H17B01.4/EMC-1	CG2943	KIAA0090
EMC2p	Y57G7A.10/EMC-2	CG17556	TTC35
EMC3p	Y62E10A.10/EMC-3	CG6750	TMEM111
EMC4p	ZK616.6/EMC-4	CG11137	TMM85
EMC5p	B0334.15/EMC-5	CG15168	MMGT
EMC6p	F33D4.7/EMC-6	CG11781	TMEM93
(-)	C35D10.1	CG8397	C15orf24
(-)	F25H2.4	CG3501	C14orf122
(-)	Y43F8C.7	CG32441	COX4NB
			C19orf63

**Table S2. Phenotypes associated with endoplasmic reticulum membrane complex inactivation**

Gene name	Embryonic lethality	Developmental arrest	Egg-laying defects	Brood size reduction	Uncoordination
<i>emc-1</i>	No	Yes	No	No	Yes
<i>emc-2</i>	No	Yes	No	No	Yes
<i>emc-3</i>	No	No	No	No	No
<i>emc-4</i>	Yes	Yes	No	Yes	No
<i>emc-5</i>	No	No	Yes	No	No
<i>emc-6</i>	Yes	Yes	No	Yes	Yes